Biogen Expands Gene Therapy Efforts Via Deals With Regenxbio, Penn
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets AAV technology license from Regenx for use in developing therapeutics for rare genetic eye disorders, which will be developed in tandem with University of Pennsylvania researchers.